XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance
Source: SeekingAlpha
2025-10-21 01:44:42 ET
XORTX Therapeutics ( NASDAQ: XRTX ) has announced that it has received an extension notice from the Nasdaq Stock Market, granting the company an additional 180 days to meet the exchange’s minimum bid price requirement of $1.00 per share....
Read the full article on Seeking Alpha
For further details see:
XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance
XORTX Therapeutics Inc.
NASDAQ: XRTX
XRTX Trading
-11.26% G/L:
$0.4082 Last:
51,735 Volume:
$0.441 Open:
XRTX Latest News
March 13, 2026 07:00:00 am
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation
March 05, 2026 07:00:00 am
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
February 04, 2026 06:00:00 pm
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
December 31, 2025 06:15:00 pm
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
XRTX Stock Data
$2,854,975
6,704,616
0.29%
8
N/A
Biotechnology & Life Sciences
Healthcare
CA
Calgary
